JAZZ PHARMACEUTICALS, INC.
PALO ALTO, CA

Jazz Pharmaceuticals plc, traded on NASDAQ under the ticker JAZZ, was originally established in Florida in February 2018 as Jazz Pharmaceuticals, Inc. The company is a globally respected name in biopharmaceuticals and focuses its efforts squarely on improving patients' lives by developing products that address unmet medical needs. Its primary areas of expertise include sleep disorders and hematology/oncology. Jazz Pharmaceuticals strategically acquires products at the late stages of development and continues to build out a pipeline of innovative therapies aimed at tackling significant health challenges worldwide. The company's headquarters is located in Palo Alto, with its main office situated at 3170 Porter Drive. Here, they cultivate an environment where patient-focused innovation thrives and employees can excel. Leadership at Jazz Pharmaceuticals comprises experienced professionals like Bruce C. Cozadd, who serves as Chairman and CEO, alongside Suzanne Sawochka Hooper (Executive VP and General Counsel) and Heather McGaughey (Senior VP of Human Resources). The team is further strengthened by Iain McGill, who manages international operations particularly in Europe, and Robert McKague, who ensures legal compliance. Registered under the Florida Model Doss.FloridaCompanyStatus with an active filing status as a For-Profit Corporation, Jazz Pharmaceuticals remains accessible via multiple contact points. The company has been consistently delivering value to its shareholders since its inception. To delve deeper into their operations, products, and corporate philosophy, interested parties can visit jazzpharmaceuticals.com.